Imbioray is a clinical-stage innovative biopharmaceutical company, the pioneer of generic off-the-shelf trained-immunity NK cells, dedicated to the research, development, and clinical application in the cell field. It has achieved comprehensive applications of ACC-NK (antibody-cell conjugate NK), ATE-NK (antibody-targeted enhanced NK), and tiNK (trained-immunity NK) in solid and hematological tumors, various non-oncological diseases, and health management.

Imbioray owns cutting-edge patented technology for NK cell immunity training and a world-class large-scale GMP production center. It is an industry standard-setter for the entire chain of NK cell preparation—from raw material collection to release and clinical application. With its high technology, efficiency, and quality, it has become a representative enterprise of national "New Quality Productive Forces."

17 pipelines have entered the registrational clinical trial stage，andACC-NKfor the treatment of solid tumors has entered Phase II of clinical trials